Electromedical Technologies
Increases
Production Following Continued Sales
to Pro
Athletes in the NBA, NFL, NHL,
PGA, and
PBR
SCOTTSDALE,
AZ -- September 15, 2020 -- InvestorsHub NewsWire
-- Electromedical
Technologies, Inc. (OTCMKTS:EMED)
(the "Company"), a pioneer in the development and manufacturing of
bioelectronic devices, is pleased to announce
that it continues to find strong interest for its
FDA
cleared WellnessPro+
device line as a bioelectronic chronic pain solution from top
professional athletes in
the NBA, NFL, NHL,
PGA,
and
PBR.
As a
result, the
Company has ordered an additional 1,000 units to enter production
to meet expected
rising
demand.
"We
are excited to see use
and growing
demand among some of the world's top athletes for our proprietary
bioelectronic chronic pain solution,
because
it represents validation from those who demand performance in their
treatment options," noted Matthew
Wolfson, Founder and CEO of Electromedical
Technologies.
"They can't afford the risks associated with opioid-based drugs,
but they need results.
Word of mouth in
locker rooms and team meetings has
been a
very valuable marketing
tool because our device delivers a complete solution to chronic
pain without any dangerous or harmful side effects
– it
helps players get up off the bench and back into the game
fast."
Management
notes that the Company has seen interest from top athletes and
trainers across the professional sports universe. The
Company is in discussions with several individuals about
cultivating public endorsements or brand ambassador relationships
based on the strong feedback Electromedical
Technologies has
received from those using the WellnessPro+
device as a
pain solution to help drive performance in professional sports
competition.
About Electromedical Technologies
Headquartered
in Scottsdale Arizona, Electromedical Technologies, Inc. is a
commercial stage, FDA cleared, bioelectronic medical device
manufacturing company initially focused on the treatment of various
chronic, acute, intractable,
and
post-operative pain conditions. Through university collaboration
agreements the company is working to develop a comprehensive
research program in defining the effects of electro-modulation on
the human body by studying the impacts of electrical fields in cell
signaling and effects on virus assembly and immune responses with
the goal of improving human wellbeing. The company's current
cleared product indications are for chronic acute post traumatic
and post-operative, intractable pain relief.
Our
animal studies do not involve any human testing, and are not
related to our current products. We are conducting this research to
augment and advance the science of electro-modulation in
healthcare. The United States Food and Drug Administration
has not reviewed or approved our animal research studies
For
more information, visit
www.electromedtech.com.
Safe
Harbor Statement
This
release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations
reflected in the forward-looking statements and the assumptions
upon which they are based are reasonable, we can give no assurance
or guarantee that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will,"
"should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. The reader is cautioned not
to put undue reliance on these forward-looking statements, as these
statements are subject to numerous factors and uncertainties,
including but not limited to: adverse economic conditions,
competition, adverse federal, state and local government
regulation, international governmental regulation, inadequate
capital, inability to carry out research, development and
commercialization plans, loss or retirement of key executives and
other specific risks. To the extent that statements in this press
release are not strictly historical, including statements as to
revenue projections, business strategy, outlook, objectives, future
milestones, plans, intentions, goals, future financial conditions,
events conditioned on stockholder or other approval, or otherwise
as to future events, such statements are forward-looking, and are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The forward-looking
statements contained in this release are subject to certain risks
and uncertainties that could cause actual results to differ
materially from the statements made.
Corporate Contact:
Electromedical
Technologies, Inc.
Matthew
Wolfson
Tel:
1.888.880.7888
email:
ceo@electromedtech.com
https://electromedtech.com
Public Relations Contact:
Tiger
Global Marketing & Branding Agency
info@TigerGMP.com
www.TigerGMP.com